Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ADORA2A | P29274 | 3/20 | 0.50 |
| ▸ | ADORA1 | P30542 | 3/20 | 0.50 |
| ▸ | TUBB4A | P04350 | 2/20 | 0.40 |
| ▸ | TUBB | P07437 | 2/20 | 0.40 |
| ▸ | TUBA3C | P0DPH7 | 2/20 | 0.40 |
| ▸ | TUBA1B | P68363 | 2/20 | 0.40 |
| ▸ | TUBA4A | P68366 | 2/20 | 0.40 |
| ▸ | TUBB4B | P68371 | 2/20 | 0.40 |
| ▸ | TUBB3 | Q13509 | 2/20 | 0.40 |
| ▸ | TUBB2A | Q13885 | 2/20 | 0.40 |
| ▸ | TUBB8 | Q3ZCM7 | 2/20 | 0.40 |
| ▸ | TUBA3E | Q6PEY2 | 2/20 | 0.40 |
| ▸ | TUBA1A | Q71U36 | 2/20 | 0.40 |
| ▸ | TUBA1C | Q9BQE3 | 2/20 | 0.40 |
| ▸ | TUBB6 | Q9BUF5 | 2/20 | 0.40 |
| ▸ | TUBB2B | Q9BVA1 | 2/20 | 0.40 |
| ▸ | TUBB1 | Q9H4B7 | 2/20 | 0.40 |
| ▸ | AXL | P30530 | 1/20 | 0.40 |
| ▸ | MKNK1 | Q9BUB5 | 1/20 | 0.40 |
| ▸ | MKNK2 | Q9HBH9 | 1/20 | 0.40 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL55563 | 0.78 | ADORA2A (0.58) | ADORA2AADORA1TUBB4ATUBBTUBA3C | |
| SCHEMBL31462939 | 0.78 | ADORA2A (0.58) | ADORA2AADORA1TUBB4ATUBBTUBA3C | |
| SCHEMBL3682651 | 0.76 | ADORA2A (0.57) | ADORA2AADORA1 | |
| SCHEMBL20589783 | 0.75 | PDE4A (0.57) | ADORA2AADORA1TUBB4ATUBBTUBA3C | |
| SCHEMBL2801448 | 0.74 | HRH4 (0.53) | ADORA2AADORA1TUBB4ATUBBTUBA3C | |
| SCHEMBL31259505 | 0.72 | HTR2C (0.61) | ADORA2AADORA1TUBB4ATUBBTUBA3C | |
| SCHEMBL31259506 | 0.72 | HTR2C (0.61) | ADORA2AADORA1TUBB4ATUBBTUBA3C | |
| SCHEMBL189594 | 0.72 | PIK3CA (0.72) | ADORA2AADORA1PIK3CAPIK3R1POLB | |
| SCHEMBL4554183 | 0.70 | PIK3CA (0.41) | ADORA2AADORA1TUBB4ATUBBTUBA3C | |
| SCHEMBL13236422 | 0.69 | ADORA2A (0.53) | ADORA2AADORA1TUBB4ATUBBTUBA3C |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | NORTHEASTERN UNIVERSITY (US) | 2010-07-15 | — | — | US | disclosed |
| EP-1349861-B1 | THIENO(3,2-d)PYRIMIDINES AND FURANO(3,2-d)PYRIMIDINES AND THEIR USE AS PURINERGIC RECEPTOR ANTAGONISTS | VERNALIS RES LTD (GB) | 2008-09-10 | — | — | EP | disclosed |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED | 2008-06-26 | — | — | US | disclosed |
| US-7384949-B2 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyrimidines and their use as purinergic receptor antagonists | VERNALIS RESEARCH LIMITED (GB) | 2008-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100178299-A1 | METHODS AND COMPOSITIONS FOR IMPROVING IMMUNE RESPONSES | HIF1AN, HIF1A, EGLN3 | ADORA2A 6/4885ADORA1 15/4885TUBB4A 4643/4885 |
| US-20080153820-A1 | Thieno(3,2-d)pyrimidines and furano(3,2-d)pyramidines and their use as purinergic receptor antagonists | CHRNA5, HTR5A, CHRNA6 | ADORA2A 6/4885ADORA1 37/4885TUBB4A 3773/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.